221 related articles for article (PubMed ID: 20942779)
1. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.
Ancrenaz V; Daali Y; Fontana P; Besson M; Samer C; Dayer P; Desmeules J
Curr Drug Metab; 2010 Oct; 11(8):667-77. PubMed ID: 20942779
[TBL] [Abstract][Full Text] [Related]
2. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ
J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
Kelly RP; Close SL; Farid NA; Winters KJ; Shen L; Natanegara F; Jakubowski JA; Ho M; Walker JR; Small DS
Br J Clin Pharmacol; 2012 Jan; 73(1):93-105. PubMed ID: 21689142
[TBL] [Abstract][Full Text] [Related]
4. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.
Small DS; Farid NA; Payne CD; Konkoy CS; Jakubowski JA; Winters KJ; Salazar DE
Clin Pharmacokinet; 2010 Dec; 49(12):777-98. PubMed ID: 21053990
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic basis of the antiplatelet action of prasugrel.
Schrör K; Siller-Matula JM; Huber K
Fundam Clin Pharmacol; 2012 Feb; 26(1):39-46. PubMed ID: 21895761
[TBL] [Abstract][Full Text] [Related]
6. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias WL; Braunwald E; Sabatine MS
Circulation; 2009 May; 119(19):2553-60. PubMed ID: 19414633
[TBL] [Abstract][Full Text] [Related]
8. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.
Hagihara K; Nishiya Y; Kurihara A; Kazui M; Farid NA; Ikeda T
Drug Metab Pharmacokinet; 2008; 23(6):412-20. PubMed ID: 19122335
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
Floyd CN; Passacquale G; Ferro A
Clin Pharmacokinet; 2012 Jul; 51(7):429-42. PubMed ID: 22568693
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
Dobesh PP
Pharmacotherapy; 2009 Sep; 29(9):1089-102. PubMed ID: 19698014
[TBL] [Abstract][Full Text] [Related]
11. Prasugrel hydrochloride for the treatment of acute coronary syndromes.
Lhermusier T; Waksman R
Expert Opin Pharmacother; 2015 Mar; 16(4):585-96. PubMed ID: 25633751
[TBL] [Abstract][Full Text] [Related]
12. Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel.
Petersen KU
Arzneimittelforschung; 2009; 59(5):213-27. PubMed ID: 19537521
[TBL] [Abstract][Full Text] [Related]
13. [Prasugrel, a new thienopyridine].
Schrör K; Huber K
Hamostaseologie; 2007 Dec; 27(5):351-5. PubMed ID: 18060245
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
Farid NA; Kurihara A; Wrighton SA
J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
[TBL] [Abstract][Full Text] [Related]
15. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Small DS; Farid NA; Li YG; Ernest CS; Payne CD; Salazar DE; Winters KJ
Curr Med Res Opin; 2008 Aug; 24(8):2251-7. PubMed ID: 18786302
[TBL] [Abstract][Full Text] [Related]
16. Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro.
Abell LM; Liu EC
J Pharmacol Exp Ther; 2011 Nov; 339(2):589-96. PubMed ID: 21828263
[TBL] [Abstract][Full Text] [Related]
17. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
[TBL] [Abstract][Full Text] [Related]
18. [Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Gratsianskiĭ NA
Kardiologiia; 2010; 50(6):4-21. PubMed ID: 20659022
[TBL] [Abstract][Full Text] [Related]
19. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Varenhorst C; James S; Erlinge D; Brandt JT; Braun OO; Man M; Siegbahn A; Walker J; Wallentin L; Winters KJ; Close SL
Eur Heart J; 2009 Jul; 30(14):1744-52. PubMed ID: 19429918
[TBL] [Abstract][Full Text] [Related]
20. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.
Wallentin L
Eur Heart J; 2009 Aug; 30(16):1964-77. PubMed ID: 19633016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
